Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;20(1):39-47.
doi: 10.1111/jth.15562. Epub 2021 Nov 8.

Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH

Lara N Roberts  1 , Ton Lisman  2 , Simon Stanworth  3   4   5 , Virginia Hernandez-Gea  6 , Maria Magnusson  7   8 , Armando Tripodi  9 , Jecko Thachil  10
Affiliations
Free article
Review

Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH

Lara N Roberts et al. J Thromb Haemost. 2022 Jan.
Free article

Abstract

Prolonged prothrombin time and thrombocytopenia are common in patients with cirrhosis. These parameters do not reflect the overall hemostatic rebalance or bleeding risk in the periprocedural setting; however, attempts to correct these parameters remain frequent. We review the literature on periprocedural bleeding risk, bleeding risk factors, and the risk and benefits of hemostatic interventions in patients with cirrhosis. We provide guidance recommendations on evaluating bleeding risk in this patient group and management of hemostatic abnormalities in the periprocedural setting.

Keywords: cirrhosis; hemorrhage; hemostasis; liver diseases; thrombocytopenia.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Lisman T, Arefaine B, Adelmeijer J, et al. Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease. J Thromb Haemost. 2021;19:85-95. doi:10.1111/jth.15112
    1. Desborough MJR, Hockley B, Sekhar M, et al. Patterns of blood component use in cirrhosis: a nationwide study. Liver International. 2016;36:522-529.
    1. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;2020:31646.
    1. O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology. 2021;161(5):1615-1627.
    1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231.